Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30524% above fair value
$63.65−0.23 (-0.36%)
Close on Nov 17, 2026Market cap $1.82BP/E 163.2Yield –
Eton Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Eton Pharmaceuticals's cash was $26.85M at Jun 30, 2026. For fiscal 2025 it was $25.94M, up 73.7% from the year before. The highest annual figure on record is $26.74M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.94M | +73.7% |
| FY2024 | Dec 31, 2024 | $14.94M | -30.2% |
| FY2023 | Dec 31, 2023 | $21.39M | +31.2% |
| FY2022 | Dec 31, 2022 | $16.31M | +13.2% |
| FY2021 | Dec 31, 2021 | $14.41M | -32.4% |
| FY2020 | Dec 31, 2020 | $21.30M | +76.5% |
| FY2019 | Dec 31, 2019 | $12.07M | -54.9% |
| FY2018 | Dec 31, 2018 | $26.74M | +103.2% |
| FY2017 | Dec 31, 2017 | $13.16M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $26.85M | +5.8% |
| Q1 FY2026 | Mar 31, 2026 | $19.66M | +12.9% |
| Q4 FY2025 | Dec 31, 2025 | $25.94M | +73.7% |
| Q3 FY2025 | Sep 30, 2025 | $37.12M | +83.2% |
| Q2 FY2025 | Jun 30, 2025 | $25.38M | +43.4% |
| Q1 FY2025 | Mar 31, 2025 | $17.42M | +4.6% |
| Q4 FY2024 | Dec 31, 2024 | $14.94M | -30.2% |
| Q3 FY2024 | Sep 30, 2024 | $20.26M | -8.2% |
| Q2 FY2024 | Jun 30, 2024 | $17.69M | -18.0% |
| Q1 FY2024 | Mar 31, 2024 | $16.66M | +13.2% |
| Q4 FY2023 | Dec 31, 2023 | $21.39M | +31.2% |
| Q3 FY2023 | Sep 30, 2023 | $22.07M | +65.0% |
| Q2 FY2023 | Jun 30, 2023 | $21.57M | +26.5% |
| Q1 FY2023 | Mar 31, 2023 | $14.71M | -3.4% |
| Q4 FY2022 | Dec 31, 2022 | $16.31M | +13.2% |
| Q3 FY2022 | Sep 30, 2022 | $13.38M | -41.1% |
| Q2 FY2022 | Jun 30, 2022 | $17.05M | -33.9% |
| Q1 FY2022 | Mar 31, 2022 | $15.23M | -39.4% |
| Q4 FY2021 | Dec 31, 2021 | $14.41M | -32.4% |
| Q3 FY2021 | Sep 30, 2021 | $22.71M | +209.7% |
| Q2 FY2021 | Jun 30, 2021 | $25.80M | +151.2% |
| Q1 FY2021 | Mar 31, 2021 | $25.11M | +103.6% |
| Q4 FY2020 | Dec 31, 2020 | $21.30M | +76.5% |
| Q3 FY2020 | Sep 30, 2020 | $7.33M | -37.7% |
| Q2 FY2020 | Jun 30, 2020 | $10.27M | -31.3% |
| Q1 FY2020 | Mar 31, 2020 | $12.34M | -37.0% |
| Q4 FY2019 | Dec 31, 2019 | $12.07M | -54.9% |
| Q3 FY2019 | Sep 30, 2019 | $11.78M | +78.4% |
| Q2 FY2019 | Jun 30, 2019 | $14.95M | +33.3% |
| Q1 FY2019 | Mar 31, 2019 | $19.58M | +48.9% |
| Q4 FY2018 | Dec 31, 2018 | $26.74M | +87.9% |
| Q3 FY2018 | Sep 30, 2018 | $6.60M | – |
| Q1 FY2018 | Mar 31, 2018 | $11.22M | – |
| Q4 FY2017 | Dec 31, 2017 | $13.16M | – |
| Q3 FY2017 | Sep 30, 2017 | $14.23M | – |
See a number that looks wrong?